What percentage of patients develop tendonitis after ciprofloxacin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Incidence of Ciprofloxacin-Associated Tendonitis

The incidence of tendonitis after ciprofloxacin use is approximately 4 per 100,000 prescriptions in the general population, though this likely represents substantial underreporting, with estimates ranging from 0.004% to 0.02% based on epidemiological studies 1.

Absolute Risk Data

The most reliable epidemiological data comes from multiple large-scale studies:

  • Primary care database studies: 4 cases per 100,000 prescriptions 1
  • French spontaneous reporting: 20 cases per 100,000 prescriptions 1
  • Prescription-event monitoring: 2.4 per 10,000 patients (0.024%) for tendinitis specifically 1

The risk difference between fluoroquinolones and reference antibiotics is 4 cases per 100,000 days of treatment 1.

High-Risk Populations

Pediatric Patients

In pediatric patients (ages 1-17 years) treated for complicated urinary tract infections, the FDA label reports significantly higher rates 2:

  • 9.3% (31/335) developed musculoskeletal adverse events within 6 weeks
  • 13.7% (46/335) reported events within 1 year
  • This compares to 6% and 9.5% in comparator groups, respectively

Lung Transplant Recipients

21.8% (22/101) of lung transplant recipients developed Achilles tendon disease, with 28% of those receiving ciprofloxacin affected 3. This represents a dramatically elevated risk compared to the general population.

Age-Stratified Risk

  • Patients ≥60 years: Substantially higher risk, with 71% of fluoroquinolone-associated tendinopathies occurring in this age group 1
  • The adjusted relative risk is 3.7 (95% CI: 0.9-15.1) for Achilles tendinitis specifically 1

Critical Risk Modifiers

Concomitant corticosteroid use dramatically amplifies risk 1:

  • In patients >60 years with concurrent corticosteroids: Relative risk increases to 6.2 (95% CI: 3.0-12.8)
  • For Achilles tendon rupture specifically with combined use: Odds ratio 43.2 (95% CI: 5.5-341.1) 1

Clinical Context

Timing of Onset

  • Median onset: 6 days after exposure (range: 2 hours to 6 months post-discontinuation) 1
  • 93% of cases occur within 1 month of exposure 1

Affected Tendons

  • 90% involve the Achilles tendon 1
  • Bilateral involvement occurs in more than half of cases 1

Recovery

  • Most patients recover within 2 months of discontinuation 1
  • 26% experience persistent pain and disability at follow-up 1

Important Caveats

The reported incidence of 0.004% (4 per 100,000 prescriptions) is widely acknowledged as substantial underreporting 1. The true incidence likely falls between 0.004% and 0.02% in the general population, but can exceed 20% in high-risk populations such as transplant recipients or those on concurrent corticosteroids.

The FDA label explicitly warns that geriatric patients are at increased risk for severe tendon disorders including rupture, with this risk further amplified by corticosteroid therapy 2. In pediatric studies, ciprofloxacin demonstrated musculoskeletal adverse event rates of 9.3% within 6 weeks, which was consistently higher than control groups across all age ranges 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.